| ★ | Obinutuzumab Achieves 95.5% Remission in INS, May Shift Steroid-Sparing Treatment Strategies | | 109 | Estados Unidos | |
| 16 | IgG4-related disease (IgG4-RD): update on diagnosis and treatments in 2025 | | 1.3K | — | 84 |
| 20 | Retatrutide Provides Substantial Weight Loss in Patients With Obesity or Overweight | | 1.1K | Estados Unidos | 84 |
| 11 | Phase 3 VISIONARY: Sibeprenlimab May Preserve #KidneyFunction in IgA Nephropathy | | 981 | Estados Unidos | 85 |
| 2 | Nefropatía por IgA en adultos Una revisión actualizada | ENSEÑANDO MEDICINA INTERNA @carloswaldomi | 690 | — | 87 |
| 19 | What is the added value of triple therapy in lupus nephritis? | | 438 | — | 84 |
| 3 | SGLT2 EN ERC Beneficio en todos los estadios | ENSEÑANDO MEDICINA INTERNA @carloswaldomi | 383 | — | 87 |
| 13 | Update on B cell targeting therapies in IgG4-related disease | | 375 | — | 85 |
| 18 | Where Kidney Biopsy Is Heading Next I #IgA Nephropathy Care | | 366 | Estados Unidos | 84 |
| 17 | TRIUMPH-2: Retatrutide Reduces Weight, A1C in Patients With Obesity | | 350 | Estados Unidos | 84 |
| 6 | Hemodiálisis incremental como forma de inicio del tratamiento sustitutivo renal | Fundación Renal Española @fundacionrenale | 275 | España | 85 |
| 12 | Interim Phase 3 VISIONARY Data Show Sibeprenlimab Preserved Kidney Function in IgA Nephropathy | | 233 | Estados Unidos | 85 |
| 1 | Kidney Compass: VISIONARY 2-Year eGFR Data in IgA Nephropathy | | 199 | Estados Unidos | 87 |
| 7 | Functional Cures for T1D: Insulin Independence Through Islet Transplantation | | 185 | Estados Unidos | 85 |
| 5 | DUPLEX Trial Results: Key Insights in #FSGS | | 71 | Estados Unidos | 85 |
| 14 | Closing Gaps in IgA Nephropathy Diagnosis and Treatment, With Brad Rovin, MD | | 60 | Estados Unidos | 85 |
| 15 | Volixibat Improves Itch, Fatigue in PSC, Supporting “Patient-Centered” Care | | 59 | Estados Unidos | 85 |
| 8 | Update 3a edición. In personalized immunosuppression | Hospital Universitari de Bellvitge @bellvitgehospital | 35 | España | 85 |
| 4 | B-Cell–Targeted Therapies Expand in IgA Nephropathy, With Samir Parikh, MD | | 27 | Estados Unidos | 86 |
| 9 | The Pathologist’s Role in IgAN Management | | 6 | Estados Unidos | 85 |
| 10 | The Pathologist’s Role in IgAN Management | | 6 | Estados Unidos | 85 |